ArticleBioMed research international2014

KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.

Seon Rang Woo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.